Will Veracyte (VCYT) Beat Estimates Again in Its Next Earnings Report?

Veracyte (NASDAQ:VCYT) Stock Price Breaks Below 200 Day Moving Average – Should You Sell?

Six Studies to Highlight Veracyte's Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026

Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test

Veracyte to Release Third Quarter 2026 Financial Results on November 4, 2026

Phase III Trial Demonstrates Veracyte's Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation